Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

NCT07046273 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tested the effects of the medication semaglutide (brand name Ozempic®) on blood sugar control in adults with type 2 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 496 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-08 · est. completion 2029-02

What this study is testing ClinicalTrials.gov NCT07046273 ↗

Description as written by the study sponsor.

This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.

Treatments tested

F027 Drug

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
Ozempic® Drug

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

Main thing measured	Change in HbA1c from baseline
Sponsor	Shandong New Time Pharmaceutical Co., LTD
Conditions studied	Type 2 Diabetes (T2DM)
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07046273 ↗